A Phase II Study of Fingolimod in Patients with Non-Small Cell and Small Cell Lung Cancer

Sponsor:
MUSC
Sponsor Study ID:
103909
CTO #:
103909
NCT Number:
NCT06424067
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lung
Study Objectives:
To determine the safety and tolerability of fingolimod in patients with NSCLC and SCLC. To evaluate the objective response rate (ORR) (when measurable) according to RECIST 1.1 criteria
eConsent:
Not available
Study Documents:
Open Study Documents
(MUSC NetID required for document access)

For more information about this trial please contact the study team:

Trial opened at the following institutions:

Medical University of South Carolina